Kornimate/medical-research-clean huggingface dataset:
enhancing oral health care use by hiv positive individuals

Conditions: Oral Health Care; HIV Infections; Mouth Diseases

Summary: the purpose of this study is to investigate the efficacy of a case management linkage intervention designed to increase utilization of oral health care services among hiv+ individuals enrolled in hiv primary care that have not seen a dental provider in the preceding twelve months.

recent national studies demonstrate that oral health is one of the highest unmet health needs for hiv-positive (hiv+) individuals, although it is recognized as playing a less critical role in the medical management of hiv/aids. social and economic factors have contributed to less than optimal use of oral health services for hiv+s in the united states. according to recent data, from miami-dade county, florida, only 24% of hiv+s served by ryan white-funded medical clinics had obtained oral health services in the past 12 months. to address the underutilization of oral health care services, we propose to develop, implement, and evaluate an intervention to assist low-income hiv+s in obtaining access to oral health services as well as increase appropriate utilization of these services. the case management intervention is adapted from an intervention that had been previously tested in a cdc-funded, multi-site study designed to link recently diagnosed hiv+s to primary medical care. a two-arm randomized trial among hiv+ individuals who are currently enrolled in hiv primary medical care, but not receiving oral health care, will be conducted to test the intervention. the two arms will consist of a case management intervention and standard-of-care. participants will be assessed at baseline and at 6, 12 and 18 months after baseline to document their utilization of oral health services. an interdisciplinary team of behavioral and clinical research scientists with experience in developing and evaluating health care and prevention intervention targeting low income, hiv+s will conduct this research.

Eligibility criteria:
inclusion criteria: * men and women 18 years and older * documented hiv infection * currently in medical care (defined as having seen an hiv primary care provider in the previous six months) * eligible for ryan white title i funding * plans to remain in miami for the next 24 months * provide the name of two verifiable locator persons exclusion criteria: * persons not meeting the inclusion criteria as delineated above

Keywords: hiv positive persons not received oral health care in the preceding 12 months. treatment naive treatment experienced
a global study of volrustomig (medi5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small cell lung cancer.

Conditions: Metastatic Non-small Cell Lung Cancer

Summary: the purpose of evolve-lung02 is to test the effectiveness (efficacy) and measure the safety of volrustomig in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy as 1l treatment in participants with mnsclc in pd-l1 \< 50%.

adult patients with a histologically or cytologically documented metastatic nsclc, with tumors that lack activating egfr, alk, and ros1 alterations are eligible for enrollment. patients will be randomized in a 1:1 ratio to receive treatment with volrustomig + chemotherapy or pembrolizumab + chemotherapy. tumor evaluation scans will be performed until disease progression as efficacy assessment. all patients will be followed for survival until the end of the study. an data monitoring committee (dmc) composed of independent experts will be convened to confirm the safety and tolerability of the proposed dose and schedule.

Eligibility criteria:
key inclusion criteria: * histologically or cytologically documented squamous or non-squamous nsclc. * stage iv nsclc (according to version 8 of the iaslc staging manual in thoracic oncology 2016), not amenable to curative surgery or radiation. * absence of sensitizing egfr mutations and alk and ros1 rearrangements. * absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted first-line therapies. key exclusion criteria: * mixed small-cell lung cancer and nsclc histology or sarcomatoid variant. rare subtypes are excluded. * spinal cord compression. * symptomatic brain metastases. brain metastases may be treated or untreated, but participants must be asymptomatic and off steroids for at least 14 days prior to start of study intervention. a minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment. * history of another primary malignancy except for: 1. malignancy treated with curative intent with no known active disease ≥ 2 years before the first dose of study intervention and of low potential risk for recurrence. 2. adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease. 3. adequately treated carcinoma in situ without evidence of disease. * as judged by the investigator, any condition that would interfere with evaluation of the study intervention or interpretation of participant safety or study results.

Keywords: metastatic non-small cell lung cancer non-squamous tumors squamous tumors pd-l1
association with low compliance bladder in women with luts

Conditions: Urinary Bladder, Overactive; Urinary Bladder Neck Obstruction; Pelvic Organ Prolapse; Urinary Incontinence

Summary: hypothesis / aims of study the clinical and urodynamic features on the severity of low compliance bladder in neurologically intact women with lower urinary tract symptoms are indeterminate. thus, this study aimed to elucidate the above association. study design, materials and methods between january 1996 and december 2021, the medical records of all consecutive women who underwent urodynamic studies for their lower urinary tract symptoms were reviewed to elucidate the clinical significance of low bladder compliance.


Eligibility criteria:
inclusion criteria: * urodynamic finding with low bladder compliance exclusion criteria: * nil.
screening for gaucher disease and acid sphingomyelinase deficiency

Conditions: Gaucher Disease

Summary: high-risk screening for gaucher disease and acid sphingomyelinase deficiency in patients with splenomegaly and/or thrombocytopenia in taiwan

late-onset gaucher disease (gd) present a unique set of challenges compared to their early-onset counterparts. symptoms may not appear until adulthood, leading to delayed diagnosis and treatment. this delay can result in irreversible damage to affected tissues and organs, such as the liver, spleen, and central nervous system. additionally, many late-onset gd are underdiagnosed or misdiagnosed due to their rarity and the variability of symptoms. this study is divided into two phases. in the first phase, patients with hepatosplenomegaly of unknown etiology will be initially screened using an electronic medical record database, and in the second phase, laboratory analysis of biomarkers, including dry blood spot (dbs) for gba1 enzyme activity, plasma lyso-gb1 levels and gba1 gene sequencing, will be performed. acid sphingomyelinase deficiency (asmd) is another lysosomal storage disorder that shares symptoms with gd. consistent with the above screening strategy for gd patients in two phases (dbs for asm enzyme activity, plasma lyso-sm levels and asm gene sequencing). this study will involve 2,000 candidates from electronic healthcare databases, 240 patients from outpatient clinics, and a cohort of 6 gd1/gd3 patients as controls. in conclusion, initial screening for late-onset gd and asmd can provide patients with treatment opportunities that can improve outcomes for those affected by these rare diseases.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of splenomegaly 2. clinical diagnosis of thrombocytopenia exclusion criteria: 1. clinical diagnosis of gaucher disease 2. clinical diagnosis of acid sphingomyelinase 3. clinical diagnosis of malignant tumors
a dengue sero-prevalence study in the metropolitan area of buenos aires

Conditions: Dengue; Flavivirus Infections

Summary: the objective of this observational study of dengue seroprevalence in the metropolitan area of buenos aires is to know what percentage of the population has antibodies against dengue in persons 18 years of age or older who are residents of the city of buenos aires or its metropolitan area. the main questions to be answered are: * what is the seroprevalence of antibodies against dengue measured by immunoglobulin g determination by elisa * characterize the different dengue serotypes in the affected population. participants will undergo a small blood draw to determine the presence of immunoglobulin g antibodies against dengue. * tests will also be performed to determine infection by flaviviruses other than dengue virus.

a two-stage stratified design will be used. the primary sampling units will be mostly defined as the census sections of the 2010 national census of population, households and dwellings. it has 5 strata, constructed through a functional relationship between the income quintiles obtained in the annual household survey (ahs) and the variables that were surveyed in the census. stratum 1 corresponds to the lowest income population, while stratum 5 corresponds to the highest. the first stage of sampling in this framework will consist of about 100 to 300 primary sampling units, called primary units areas, selected with a probability proportional to size, the measure of size being the total number of dwellings. a sample of 1,487 dwellings is proposed. in each primary unit area, a number of dwellings will be selected to be visited by enumerators, who will make a list of all members residing in the dwelling (regardless of whether they are from the same household) and select a member aged ≥18 years to proceed with the survey. this last selection is a 3rd and final sampling stage that will define the sample of 1487 participants to be tested. the sample size was calculated based on the estimated probability of pre-infection for each of the municipalities and localities participating in the survey.

Eligibility criteria:
inclusion criteria: * - age ≥18 at the time of signing the informed consent. * - resident of the buenos aires metropolitan area exclusion criteria: * to be ≤17 years old. * inability to give informed consent.
pharmacokinetic study for anti-tuberculosis drugs

Conditions: Pulmonary Tuberculosis

Summary: the purpose of this study is to evaluate the effect of food on pharmacokinetic profile of multiple doses orally administered first-line anti-tuberculosis drugs in subjects with pulmonary tuberculosis.

this is a single-center, open-label, randomized, two way crossover design, pharmacokinetics study. 1. treatment a: study agents (rifater+emb) will be given approximately 45 minutes prior to breakfast. 2. treatment b: study agents (rifater+emb) will be given approximately 45 minutes after the breakfast is finished.

Eligibility criteria:
inclusion criteria: 1. age greater than 20 years 2. karnofsky score of \> 50 3. clinical and radiographic signs and symptoms consistent with pulmonary tb determined by the investigator. 4. a documented positive microbiology diagnosis results which indicate highly suspected pulmonary tuberculosis. 5. anti-tb drugs treatment with of ethambutol, isoniazid, rifampin and pyrazinamide. 6. willing to be hospitalized per standard of care for at least 6 days from first does of anti-tb drugs administered. 7. start anti-tb chemotherapy for at least 2 days prior to participate in the study. 8. the subject is able to understand and comply with protocol requirements, and follow the instructions and protocol-stated restrictions. 9. only subjects who have provided signed and dated written informed consent will be included. exclusion criteria: 1. previously treated for mdr-tb, xdr-tb or likely to require surgical procedure for management of tb 2. alcohol or drug abuse that would interfere with the ability to meet study requirements (in the opinion of investigator) 3. concomitant disorders or conditions for which ethambutol, isoniazid, rifampin or pyrazinamide are contraindicated. 4. unable to meet selected safety criteria obtained at screening (laboratory parameters, etc.) 5. women who are pregnant or breastfeeding during the study period. 6. subjects with a known allergy to study drugs 7. in the opinion of the investigator to be unsuitable for study participation for any reason.

Keywords: tuberculosis pharmacokinetic first-line drugs
effectiveness and safety of different antithrombotic therapy for the treatment of ventricular thrombus

Conditions: Ventricular Thrombus

Summary: to observe the effectiveness and safety of different therapies-non-vitamin k antagonist oral anticoagulants (noacs) or vitamin k antagonists (vkas) or antiplatelet agents and non-antithrombotic therapy - for the treatment of vt.


Eligibility criteria:
inclusion criteria: * adults with ventricular thrombus(vt), regardless of sex, basic diseases, occupation or education; * the vt should be found newly within 3 months; * the observational phase should last until the time that patients who had achieved thrombus resolution. the following up period after the phase ended should continue for at least 3 months. exclusion criteria: * individuals received standard antithrombotic therapy within 4 weeks; * individuals received the thrombectomy therapy, ventricular aneurysm resection or heart transplantation within 6 weeks since the vt was found in the first time; * had a long history of vt more than three months.
evaluation of arthroscopic reconstruction of the anterior cruciate ligament by one night hospital stay or by day surgery: a randomised, prospective clinical trial

Conditions: Rupture of the Anterior Cruciate Ligament With Instability of the Knee Joint

Summary: patients who suffered from a rupture of the anterior cruciate ligament with instability of the knee joint, will be treated with an operative acl-reconstruction. one group of patients will stay one night in the hospital and go home the other day (group i). the other group of patients will go home the same day of surgery (group ii). all patients will undergo the same arthroscopic reconstruction of the acl. anesthesia will be performed on each patient in a classic manner. at the end of the surgery each group of patients will be randomly divided in two subgroups: one group will get an injection in the knee joint with 20 ml of physiological fluid (group ia en iia), the other group will get an injection in the knee joint with 20 ml of chirocaine 0.125%, a widely used pain-medicine (group ib and iib). this will happen in a double blind, randomized way. the whole procedure takes about one hour. after surgery patients are brought to the recovery room and are observed every 30 minutes for the duration of 4 hours. before being brought to their rooms, patients will have to fill in a vas: visual analogue scale, to determine their pain. after being brought to their rooms, the patients will have the choice of going home the same day or staying in the hospital for one night, according to the amount of pain they are in. that moment it will be possible to switch groups. patients who go home the same day of surgery will be contacted by phone the day after to fill in a question form. patients who were admitted for one night will be seen before their leave to fill in the same question form.


Eligibility criteria:
inclusion criteria: * patients who suffered from a isolated rupture of the anterior cruciate ligament with instability of the knee joint will be included in the study. * patients with a meniscal tear that can be sutured will also be included. partial meniscectomies are accepted. exclusion criteria: * patients with chronic laxity (longer than 9 months), associated collateral laxity (grade iii), subtotal or total meniscectomy, infection or inflammatory disease of the knee joint or large cartilage lesion will not be included in the study.
mk0249 for the treatment of cognitive impairment in patients with schizophrenia (0249-016)

Conditions: Paranoid Schizophrenia

Summary: the purpose of this study is to determine the safety and effectiveness of an investigational drug mk0249 for the treatment of the cognitive impairment in patients with schizophrenia.


Eligibility criteria:
inclusion criteria: * patient is clinically stable, on current antipsychotic medication for at least 3 months and current dose for 2 months * patient has a 6th grade reading level or better * females are not pregnant, and those who can have children agree to remain abstinent or use acceptable birth control throughout the study * patient has had a stable living arrangement for at least 3 months prior to study start * patient is in general good health based on screening assessments * patient has total positive and negative syndrome scale (panss) score between 36 and 75 at screening and at the first baseline visit * patient has a clinical global impressions - severity (cgi-s) score less than or equal to 4 at screening and at the first baseline visit exclusion criteria: * patient has a major disease/disorder that may interfere with cognitive testing (such as mental retardation) and/or pose a risk upon study participation * patient has a history of head trauma with loss of consciousness greater than 15 minutes * patient has had warfarin treatment, mao inhibitors, clonazepam or clozapine within 1 month of screening * patient has had ect treatment within 6 months of screening * patient requires treatment with antihistamines or certain other medications listed in the protocol * patient has a history of liver disease that has been active within the last 2 years, or a history of cancer within the past 5 years * patient has a history of alcohol or drug dependence within the past year or alcohol or drug abuse within 3 months of screening

Keywords: undifferentiated schizophrenia residual schizophrenia
the impact of roto track® in helping patients with diabetes rotate their insulin injections better

Conditions: Diabetes

Summary: the roto track® is an electronic injection form and injection log for keeping track of injection sites in the abdominal region. the device attaches directly to the insulin pen and activates whenever the insulin pen is picked up. small led lights on the device will indicate where the next injection site is according to the individual patient's injection plan. by moving the pen and device to an "anchor point" in front of the navel, the device is able to start tracking where the insulin pen is being moved to. the device additionally contains a haptic interface to indicate to the user when the device has been moved to the next area in the injection plan. the device registers the location, the time and the dosage automatically when the patient injects insulin with the pen the rationale of the trial is that the roto track® can help patients rotate their injections sites and that this will provide the healthcare system with a new cost-effective tool for improving insulin injection techniques.

both observational and interventional studies have reported that proper rotation of injection sites can be obtained through intensive injection technique training, education and follow up of patients. furthermore, this has significant beneficial effects on daily glycaemic variations, hypoglycaemic events, long term blood glucose levels, and insulin dose requirements. this is however frequently not done appropriately in every day practice. at a small workshop at nordsjællands hospital in november 2017 with patients with type 1 diabetes the value of a device to registrar time, dose and rotation of insulin injections were discussed. all patients considered their own injection patterns as satisfying - although only one in four used a systematic approach. most patients relied on their healthcare provider to identify side effects like lipohypertrophy, half of the patients re-used needles more than once and two took injections through the clothes now and then. all subjects would prefer a simple and small device to be used with the pen for the lifetime of the pen to minimize time used for injections and attraction of attention from other people. the hypothesis is that the roto track® can reduce the number of insulin injections in the same subcutaneous skin area as compared with standard insulin injection instructions in patients with type 1 diabetes. the reduction of injection in same skin area will be quantified by a rotation score

Eligibility criteria:
inclusion criteria: 1. written informed consent obtained before any trial related procedures are performed 2. male or female aged 18 years 3. type 1 diabetes with a duration of two or more years 4. treated with three or more daily pen injections of novo rapid™ in the abdominal region 5. the subject must be willing and able to comply with trial protocol exclusion criteria: 1. blind or severely impaired eyesight 2. history of alcohol or drug abuse
regional distribution of ventilation at different respiratory rates

Conditions: Mechanical Ventilation; Atelectasis; Distribution of Ventilation

Summary: this study will investigate the distribution of gas during mechanical ventilation in patients undergoing robot assisted laparoscopic prostatectomy. the gas distribution of ventilation are monitored and data extracted using electric impedance tomography in different respiratory rates.

mechanical ventilation during anaesthesia and intensive care often results in an uneven gas distribution of ventilation. patients anaesthetized for laparoscopic surgery and patients positioned i a trendelenburg position is particularly at risk. a less harmful mode of ventilation could possible lead to a more optimal ventilation with avoidance of ventilator induced lung injuries. the project will investigate if volume controlled ventilation with a higher respiratory frequency can be used in this purpose. the researchers intend to investigate patients, without previously known lung disease, undergoing robot-assisted laparoscopic prostatectomy. after the patients have given informed consent, they will be included in the project. the distribution of ventilation will be monitored with electric impedance tomography (eit). once the patients have been anaesthetized, positioned with the head down and the surgical procedure have been started with insufflation of carbon dioxide we will start our test. the investigators will perform three episodes of standardized ventilation with the respiratory rate (rr) of 20, 40 and 60. with a higher rr the tidal volume will be reduced tom maintain a constant inhaled minute volume. data will be collected from the eit-equipment, the anaesthesia machine and the monitoring system.

Eligibility criteria:
inclusion criteria: * patients planned for robot-assisted laparoscopic prostatectomy * \> 18 years * consent to take part in the study exclusion criteria: * impaired cognitive function * previously known lung disease * insufficient skills in swedish language to understand information about the study
prevalence and risk factors for pain and related adverse reactions among breast cancer survivors on aromatase inhibitors

Conditions: Breast Cancer; Aromatase Inhibitors; Endocrine Therapy; Pain; Anxiety; Depression; Sleep

Summary: we obtained the occurrence of pain sensation, pain mood, sleep, etc. during endocrine therapy in breast cancer patients through telephone follow-up, and analyzed risk factors through artificial intelligence


Eligibility criteria:
inclusion criteria: - breast cancer survivors on aromatase inhibitors exclusion criteria: * advanced breast cancer